Skip to main content

Table 2 Etiology of kidney disease and duration of dialysis among studied groups

From: The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial

 

Niacin group

(n = 25)

Control group

(n = 25)

P value

Duration of dialysis (in years)

Range

2.82 ± 1.78

1–5

2.28 ± 0.98

1–4

0.49

Etiology

  

0.16

 HTN

11 (44%)

10 (40%)

 Obstructive uropathy

10 (40%)

7 (28%)

 Diabetes mellitus

3 (12%)

4 (16%)

 Glomerulonephritis

1 (4%)

3 (12%)

 Polycystic kidney

0

1 (4%)

  1. Data expressed as frequency (percentage), mean (SD). P value was significant if < 0.05